All articles by Ranjith Dharma

1. Amgen receives FDA approval for Kyprolis combination therapy to treat multiple myeloma

   The US Food and Drug Administration (FDA) has granted approval for Amgens’ Kyprolis (carfilzomib) combination therapy to treat patients with…
   Read More…

   21 Jan
2. Pharma companies urge governments to take collective action on drug-resistant infections

   Around 85 international pharmaceutical, generics, diagnostics and biotechnology firms have urged governments and industry to take comprehensive action on drug-resistant…
   Read More…

   21 Jan
3. AbbVie’s venetoclax-rituximab combination gets FDA breakthrough therapy status to treat R/R CLL

   Biopharmaceutical firm AbbVie has received breakthrough therapy status from the US Food and Drug Administration (FDA) for its venetoclax in…
   Read More…

   20 Jan
4. Upsher-Smith and Saniona to develop new therapeutics for neurological disorders

   Upsher-Smith Laboratories wholly-owned subsidiary Proximagen has partnered with biotech firm Saniona to develop novel therapeutics for neurological disorders. Under the…
   Read More…

   20 Jan
5. Acorda to acquire Finland’s biopharmaceutical firm Biotie for $363m

   Acorda Therapeutics has signed an agreement to acquire Finland-based biopharmaceutical firm Biotie Therapies for approximately $363m. Based in Turku, Biotie…
   Read More…

   19 Jan
6. MediciNova’s ibudilast gets FDA rare paediatric disease status to treat Krabbe disease

   MediciNova has received rare paediatric disease status from the US Food and Drug Administration (FDA) for its MN-166 (ibudilast) to…
   Read More…

   18 Jan
7. Wellstat’s Vistogard receives FDA approval to treat chemotherapy overdose patients

   Wellstat Therrpeutics has received approval from the US Food and Drug Administration (FDA) for its Vistogard (uridine triacetate) to treat…
   Read More…

   13 Dec
8. Court rules UK firm Reckitt Benckiser’s Nurofen made misleading pain relief claims

   The Federal Court of Australia has ruled that UK-based Reckitt Benckiser’s Nurofen made misleading pain relief claims. According to the…
   Read More…

   13 Dec
9. Omnio and ProMetic partner to develop new drug for chronic wounds

   Switzerland-based biotech firm Omnio has teamed-up with Canadian pharmaceutical firm ProMetic to develop a new drug for slow-healing chronic wounds….
   Read More…

   16 Nov
10. Baxalta receives European approval for Obizur to treat haemophilia A

    Baxalta has received marketing approval from the European Commission for its Obizur (Antihaemophilic Factor [ecombinant], Porcine Sequence) to treat adult…
    Read More…

    15 Nov